A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer
- 1 October 1990
- journal article
- research article
- Published by Wiley in BJOG: An International Journal of Obstetrics and Gynaecology
- Vol. 97 (10) , 922-929
- https://doi.org/10.1111/j.1471-0528.1990.tb02448.x
Abstract
Summary. Age, ultrasound score, menopausal status, a clinical impression score and serum CA 125 level were assessed to see how they could best distinguish between patients with benign (n = 101) and malignant (n – 42) pelvic masses. Each criteria used alone provided statistically significant discrimination. The most useful individual criteria were a serum CA 125 level of 30 U/ml (sensitivity 81 %, specificity 75%) and an ultrasound score of 2 (sensitivity 71%, specificity 83%). Three criteria could be combined in a risk of malignancy index (RMI) which is simply calculated using the product of the serum CA 125 level (U/ml), the ultrasound scan result (expressed as a score of 0, 1 or 3) and the menopausal status (1 if premenopausal and 3 if postmenopausal). This index was statistically virtually as effective a discriminant between cancer and benign lesions as more formal methods. Using an RMI cut‐off level of 200, the sensitivity was 85% and the specificity was 97%. Patients with an RMT score of greater than 200 had, on average, 42 times the background risk of cancer and those with a lower value 0.15 times the background risk.This publication has 17 references indexed in Scilit:
- Transvaginal colour flow imaging: a possible new screening technique for ovarian cancer.BMJ, 1989
- Tribute to Patrick Steptoe: beginnings of laparoscopyHuman Reproduction, 1989
- The CA 125 tumour-associated antigen: a review of the literatureHuman Reproduction, 1989
- The value of preoperative serum CA 125 levels in patients with a pelvic massAmerican Journal of Obstetrics and Gynecology, 1988
- Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses. Discrimination of benign from malignant diseaseAmerican Journal of Obstetrics and Gynecology, 1988
- Tumor Antigen Nb/70K and Ca 125 Levels in the Blood of Preoperative Ovarian Cancer Patients and Controls: A Preliminary Report of the use of the Nb12123 and Ca 125 Radioimmunoassays Alone and in CombinationThe International Journal of Biological Markers, 1988
- MULTIMODAL APPROACH TO SCREENING FOR OVARIAN CANCERThe Lancet, 1988
- Pre-operative discrimination between benign and malignant ovarian tumors using a combination of CA125 and CA15.3 serum assaysInternational Journal of Cancer, 1988
- Staging laparotomy in early ovarian cancerJAMA, 1983
- DISTINCTION OF BENIGN FROM MALIGNANT OVARIAN CYSTS BY ULTRASOUNDBJOG: An International Journal of Obstetrics and Gynaecology, 1978